By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
Medical Information, Documents, News - TheMediTary.Com Logo Medical Information, Documents, News - TheMediTary.Com Logo

TheMediTary.Com

Medical Information, Documents, News - TheMediTary.Com

  • Home
  • News
  • Drugs
  • Drugs A-Z
  • Medical Answers
  • About Us
  • Contact
Medical Information, Documents, News - TheMediTary.Com Logo Medical Information, Documents, News - TheMediTary.Com Logo
Search Drugs
  • Drugs
    • Latest Drugs
    • Drugs A-Z
    • Medical Answers
  • News
    • FDA Alerts
    • Medical News
    • Health
    • Consumer Updates
    • Children's Health
  • More TheMediTary.Com
    • About Us
    • Contact
Follow US
Home > Drugs > Antidiabetic combinations > Ertugliflozin and sitagliptin > Ertugliflozin / Sitagliptin Dosage
Antidiabetic combinations
https://themeditary.com/dosage-information/ertugliflozin-sitagliptin-dosage-11200.html

Ertugliflozin / Sitagliptin Dosage

Drug Detail:Ertugliflozin and sitagliptin (Ertugliflozin and sitagliptin [ er-too-gli-floe-zin-and-si-ta-glip-tin ])

Drug Class: Antidiabetic combinations

Contents
Uses Warnings Before Taking Dosage Side effects Interactions

Usual Adult Dose for Diabetes Type 2

Initial dose: 1 tablet (ertugliflozin 5 mg/sitagliptin 100 mg) orally once a day

  • For patients tolerating therapy and requiring additional glycemic control, may increase to 1 tablet (ertugliflozin 15 mg/sitagliptin 100 mg) orally once a day
Maximum dose: ertugliflozin 15 mg/sitagliptin 100 mg per day

For patients already receiving ertugliflozin: Switch to combination product with same ertugliflozin dose

Comments:
  • Volume depletion should be corrected prior to initiating therapy.
  • This drug is not recommended for patients with type 1 diabetes mellitus as it may increase the risk of diabetic ketoacidosis in these patients.
  • This drug has not been studied in patients with a history of pancreatitis; it is not known whether this may increase the risk of developing pancreatitis during therapy.

Use: As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

Renal Dose Adjustments

eGFR 45 mL/min/1.73 m2 or greater: No dose adjustment recommended
eGFR less than 45 mL/min/1.73 m2): Not recommended
Severe renal impairment (eGFR 30 mL/min/1.73m2), ESRD, or dialysis: Contraindicated

Liver Dose Adjustments

Mild to moderate hepatic impairment: No dose adjustment recommended
Severe hepatic impairment: Not recommended

Dose Adjustments

Elderly: No dosage adjustment recommended based on age: elderly patients are more likely to have renal impairment; assess renal function more frequently

Concomitant Use of Insulin and Insulin Secretagogues:

  • A lower dose of insulin or an insulin secretagogue may be required to reduce the risk of hypoglycemia.

Precautions

CONTRAINDICATIONS:

  • Hypersensitivity to active substances or product excipients; reactions such as anaphylaxis or angioedema have occurred
  • Severe renal impairment (eGFR less than 30 mL/min/1.73 m2), ESRD, or dialysis

Safety and efficacy have not been established in patients younger than 18 years.

Consult WARNINGS section for additional precautions.

Dialysis

Contraindicated

Other Comments

Administration advice:

  • Take orally once a day in the morning, with or without food

Missed dose: If a dose is missed, take as soon as remembered; do not double next dose.

General:
  • Correct volume depletion prior to initiating treatment.
  • Not recommended for patients with type 1 diabetes mellitus.
  • Has not been studied in patients with a history of pancreatitis; it is unknown whether these patients may be at an increased risk for the development of pancreatitis.

Monitoring:
  • Assess fluid status prior to initiation and monitor for signs and symptoms of volume depletion during therapy
  • Obtain renal function prior to initiating therapy and as clinically indicated
  • Evaluate for the presence of ketoacidosis in symptomatic patients, regardless of blood sugar reading
  • Monitor for new pain or tenderness, sores or ulcers, or infections involving the leg or foot
  • Monitor for pancreatitis
  • Monitor for signs and symptoms of heart failure
  • Monitor for genital mycotic infections and urinary tract infections
  • Monitor glycemic control

Patient advice:
  • Read the US FDA-approved patient labeling (Medication Guide).
  • Instruct patients experiencing symptoms of ketoacidosis such as difficulty breathing, nausea, vomiting, abdominal pain, confusion, and unusual fatigue, or sleepiness to stop taking this drug and seek immediate medical attention.
  • Patients should be instructed to maintain adequate fluid intake to avoid adverse reactions related to volume depletion such as orthostatic hypotension.
  • Patients should understand the importance of adhering to dietary instructions, regular physical exercise, and routine lab monitoring; they should understand how to treat low and high blood sugars and when to seek medical advice (for example, during periods of stress as medical management of glycemic control may change).
  • Inform patients that genital mycotic infections, urinary tract infections, and hypersensitivity reactions may occur; patients should be instructed to contact their health care professional.
  • Patients should be instructed to seek immediate medical attention for symptoms of tenderness, redness, or swelling of the genitals or the area from the genitals back to the rectum, especially if they have a fever and are feeling unwell.
  • Patients should be instructed to seek medical attention promptly for signs and symptoms of acute kidney injury such as decreased urine, swelling in the legs or feet.
  • Patients should be instructed to promptly report new pain or tenderness, sores or ulcers, or infections involving the leg or foot.
  • Instruct patient to report signs and symptoms of pancreatitis; if persistent, severe abdominal pain occurs, seek medical advice promptly.
  • Women of childbearing potential should be advised to speak to their healthcare provider if they become pregnant, intend to become pregnant, or are breastfeeding.
  • Instruct patients to contact their health care provider if they develop severe and persistent joint pain.
Share this Article
Latest News
Medical News

Shingles vaccine may lower heart disease risk by up to 8 years

May 09, 2025
Obesity, unhealthy lifestyles may cause heart to age by 5–45 years
Aging: As little as 5 minutes of exercise may keep the brain healthy
Prostate cancer: Simple urine test may help with early detection
Cancer treatment side effects: Exercise may reduce pain, fatigue
Alzheimer's: Exercising in middle age may reduce beta-amyloid in brain...
Related Drugs
Fidanacogene Elaparvovec
Cerave Anti-Itch
Centrum Adult
Crovalimab
Cyltezo Prefilled Syringe
Zepbound Pen
Mylanta One
Uretron Ds
Medihoney Wound And Burn Dressing
Lidotrode

Other drugs

Name Drug Class Updated
Fidanacogene Elaparvovec Drugs 03-Oct-2024
Cerave Anti-Itch Drugs 02-Oct-2024
Centrum Adult Drugs 02-Oct-2024
Crovalimab Drugs 02-Oct-2024
Cyltezo Prefilled Syringe Drugs 01-Oct-2024
Zepbound Pen Drugs 30-Sep-2024
Mylanta One Drugs 27-Sep-2024
Uretron Ds Drugs 27-Sep-2024
Medihoney Wound And Burn Dressing Drugs 26-Sep-2024
Lidotrode Drugs 26-Sep-2024
Libervant Drugs 26-Sep-2024
Moderna Covid-19 Drugs 25-Sep-2024
Beqvez Drugs 24-Sep-2024
Beqvez Drugs 24-Sep-2024
Beqvez Drugs 24-Sep-2024

Categories

  • FDA Alerts
  • Medical News
  • Health
  • Consumer Updates
  • Children's Health

About US

Welcome to TheMediTary.Com

Our website provides reliable and up-to-date information on various medical topics. We empower individuals to take charge of their health by simplifying complex medical jargon and providing practical tips and advice. We prioritize the privacy and confidentiality of our users and welcome feedback to improve our services.

Website use data of FDA and other sources

DMCA.com Protection Status Truste Protection Status Trust Mark Protection Status
HONcode logo We comply with the HONcode standard for trustworthy health information.
Quick Link
  • About Us
  • Contact Us
  • Editorial Policy
  • Privacy Policy
  • Accessibility Policy
  • Terms & Conditions
  • Disclaimer
  • DMCA
  • Do Not Sell My Personal Information
  • Sitemap
  • Care Notes
  • Health Guide
  • Professional
Drugs
  • New Drugs
  • Medical Answers
  • Drugs A-Z
  • Drug Classes
  • Drug Dosage
  • Pill Identifier
  • Consumer Infor
  • Side Effects
  • Inactive Ingredients
  • Pregnancy Warnings
  • Patient Tips
  • Treatments
News
  • Latest News
  • FDA Alerts
  • Medical News
  • Health
  • Consumer Updates
  • Children's Health
Find US
  • Medium
  • Google Site
  • Blogspot
  • API
  • Reddit
  • Tumblr
  • Scoop.it
  • Substack
  • Wordpress
  • Wix
  • Behance

© 2025 TheMediTary.Com All rights reserved. Operated by